Adaptive Biotechnologies Corp
ADPT
Market Cap$2.01B
Close$
$3.64
71.7% downside
Current Fair Value
71.7% downsideOvervalued by 71.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.01 Billion |
|---|---|
| Enterprise Value | $2.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.93 |
| Outstanding Shares | 152,082,284 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -16.53 |
|---|---|
| PEG | 37.09 |
| Price to Sales | 12.85 |
| Price to Book Ratio | 12.85 |
| Enterprise Value to Revenue | 10.25 |
| Enterprise Value to EBIT | -17.71 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.78 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...